SGS Expands Biopharmaceutical Services with New Stability Studies Capabilities in Birsfelden Laboratory

SGS Expands Biopharmaceutical Services with New Stability Studies Capabilities in Birsfelden Laboratory

(IN BRIEF) SGS has expanded its laboratory in Birsfelden, Switzerland, to offer comprehensive stability studies as part of its biopharmaceutical service portfolio. Effective February 2024, the enhanced facility provides integrated services including controlled temperature storage and various analytical tests, ensuring compliance with industry guidelines. With a new state-of-the-art 550 sqm facility and increased staffing, SGS aims to meet rising client demand and enhance service capabilities, anticipating further advancements in technologies like qPCR and MFI to support future growth.

(PRESS RELEASE) GENEVA, 20-Jun-2024 — /EuropaWire/ — In a significant enhancement to its biopharmaceutical services, SGS has expanded its laboratory in Birsfelden, Switzerland, to include comprehensive stability studies as part of its service portfolio. This development, effective February 2024, bolsters the laboratory’s offerings with advanced capabilities in sample storage and analytical services, catering to the precise needs of SGS customers in the biopharmaceutical sector.

The expanded facility now provides a full suite of integrated services, including stability storage under controlled temperature and humidity conditions spanning from -80°C to +25°C, compliant with ICH Q5C guidelines. Additionally, the laboratory offers a spectrum of analytical services such as QC analytics, physicochemical analytics, and bioassays.

SGS emphasizes a streamlined customer experience with dedicated project managers serving as single points of contact. These managers oversee project execution, ensuring adherence to budgets and timelines while offering flexible solutions tailored to client requirements.

The laboratory’s newly constructed 550 sqm space features state-of-the-art facilities, including dedicated areas for sample reception, stability chambers, and analytical laboratories. With 24/7 access control and monitoring, the facility optimizes efficiency in sample processing and analysis, supporting rapid turnaround times crucial to meeting customer deadlines.

Notably, the stability storage section comprises advanced climate cabinets and freezers equipped to handle rigorous environmental conditions. With redundant chambers ensuring reliability, the facility accommodates the increasing demand for stability studies with room for future expansion.

To meet the growing demand and maintain service excellence, SGS plans to expand its workforce at the Birsfelden laboratory, reinforcing its commitment to delivering high-quality biopharmaceutical services.

Looking ahead, SGS anticipates continued growth in its capabilities, exploring additional technologies like qPCR, MFI, and SoloVPE to further enhance its service offerings and support the evolving needs of the biopharmaceutical industry.

About SGS Health Science

SGS Health Science is a division of SGS, the world’s leading testing, inspection and certification company. Its global network of analytical testing, formulation, clinical research and clinical manufacturing solutions offers a wide range of integrated services and expertise across America, Europe and Asia-Pacific.

SGS Health Science experts support customers throughout the development and commercial manufacture of their drug products, helping ensure the delivery of safe, effective and compliant medicines to markets.

About SGS

We are SGS – the world’s leading testing, inspection and certification company. We are recognized as the global benchmark for sustainability, quality and integrity. Our 99,600 employees operate a network of 2,600 offices and laboratories around the world.

Media Contact:

Bernhard Schnurr
Health Science – Site Manager
SGS Health Science
t: +41 61 204 0800
Web: sgs.com/analytics

SOURCE: SGS